Please describe your experience in treating Wet AMD, what are the treatment options available to you and which ones you choose to use in your practice?

What do you think on how the Phase 2 trial of DE-122 is structured? With 51 patients enrolled, at 4 hospitals in Philippines, and Lucentis (Ranibizumab) being administered in all 3 arms, but it’s side effects include conjunctival haemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation and arterial thromboembolic events. Could this potentially disturb the safety and efficacy results of DE-122?

What is the underlying mechanism of action of TRC105, the main active component of DE-122, and could you speak more broadly about endoglin antibodies in the ophthalmic space? 

• And what are the reasons to believe that the drug would show a clinically meaningful change in best corrected visual acuity?
  

The company’s management are aiming for DE-122 to be used in combination with VEGF inhibitors. What are your thoughts on that, under what circumstances would you consider this combination a viable treatment option?

• What makes the VEGF inhibitors the standard of care in wet AMD at the moment?
  

Data from Santen’s completed Phase 1/2 PAVE trial of DE-122 is still due to come in the 1st half of 2018, even though it has been completed since July 2017. Is this a reasonable timeframe for a Phase 1 trial?